Abstract 1898P
Background
Over the last decade there has been increased number of adolescent and young adults undergoing cancer-related treatments due to increased number of cancer diagnosis. For cancer patients, VR has been shown to be more effective than other forms of distraction for relieving anxiety, depression, and fatigue during chemotherapy. There is also a great variation of VR environments described in the literature from game playing to relaxing environment settings in nature.
Methods
The review was performed according PRISMA guideliness using search terms related to digital health, virtual reality, neoplasm, cancer, adolescent, young adults, treatment, oncology, home care, virtual environments to identify studies indexed in: MEDLINE(Ovid), PubMed, PsycInfo, Scopus, EMBASE, CINAHL in English language published from 2012-2022., in cancer patients aged 18 - 25 years old.
Results
The search yielded 823 initial records, including randomized controlled and case-controlled trials. For cancer patients, VR has been shown to be more effective than other forms of distraction for relieving anxiety, depression, and fatigue during chemotherapy. There is also a great variation of VR environments described in the literature from game playing to relaxing environment settings in nature. However there is not sufficient literature describing evidence in home-based settings of cancer patients receiving chemotherapy or any other oncology active treatments. Patients using HADS-D on average, had a 15% decrease in depression, 13% decrease in general anxiety after receiving the VR intervention. Their perception of pain decreased by 18%. Results were supported by the objective measures.
Conclusions
The availability of affordable commercial VR hardware has paralleled a growing interest in the use of the technology in the health sector. In the context of cancer care, there is a small but growing body of research into the use of VR technology. Findings hold significant potential for improving the support and care of cancer patients in remote settings. Key insights contribute to the advancement of patient-centered care strategies, fostering innovation in telemedicine and enhancing delivery of supportive services to individuals facing cancer diagnoses.
Clinical trial identification
379260.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1884P - Development and validation of a prediction tool for severe treatment-related toxicities in older cancer patients on systemic treatment (TR-TRM)
Presenter: Wendy Chan
Session: Poster session 12
1885P - Serum ATG5 protein may determine chemotherapy-related cognitive dysfunction in older patients with cancer
Presenter: Ozgur Tanriverdi
Session: Poster session 12
1886P - Expectations and priorities of older patients with cancer: The PRIORITY multicenter cohort study
Presenter: Thomas Grellety
Session: Poster session 12
1887P - Effect of logotherapy on chronic sorrow, dignity, and meaning in life of palliative care patients
Presenter: Yasemin Eskigulek
Session: Poster session 12
1888P - PalliScore: Validation of a rapid scoring system for enhancing decision-making in the Emergency Department for cancer patients in palliative care
Presenter: Rafael Carmo
Session: Poster session 12
1889P - Addressing unmet needs in the management of persistent severe cancer pain: European expert recommendations
Presenter: Mario di Palma
Session: Poster session 12
1890P - End-of-Life (EOL) systemic anticancer treatment (SACT) and health services use before and during the COVID-19 pandemic
Presenter: Javaid Iqbal
Session: Poster session 12
1891P - The effects of glucagon-like peptide 1 agonists on immune checkpoint inhibitor-associated cardiotoxicity
Presenter: Cho Han Chiang
Session: Poster session 12
1892P - Glucagon-like peptide 1 agonists and anthracycline-associated cardiotoxicity in hematologic malignancies
Presenter: Cho Hung Chiang
Session: Poster session 12
1893P - Incidence of myocardial ischemia during treatment with capecitabine: Assessment with Holter recording and cardiac biomarkers
Presenter: Anne Dyhl-Polk
Session: Poster session 12